Artificial intelligence (AI) Archives - Page 2 of 2 - Sanford Burnham Prebys
Institute News

NIH director highlights Sanford Burnham Prebys and National Cancer Institute project to improve precision oncology

AuthorGreg Calhoun
Date

May 9, 2024

The NIH director’s blog features a recent publication detailing the study of a new AI tool that may be able to match cancer drugs more precisely to patients.

Monica M. Bertagnolli, MD, director of the National Institutes of Health (NIH), highlighted a collaboration between scientists at Sanford Burnham Prebys and the National Cancer Institute (NCI) on the NIH director’s blog. Bertagnoli noted advances that have been made in precision oncology approaches using a growing array of tests to uncover molecular or genetic profiles of tumors that can help guide treatments. She also recognizes that much more research is needed to realize the full potential of precision oncology.

The spotlighted Nature Cancer study demonstrates the potential to better predict how patients will respond to cancer drugs by using a new AI tool to analyze the sequences of the RNA within each cell of a tumor sample. Current precision oncology methods take an average of the DNA and RNA in all the cells in a tumor sample, which the research team hypothesized could hide certain subpopulations of cells—known as clones—that are more resistant to specific drugs.  

Bertagnoli said, “Interestingly, their research shows that having just one clone in a tumor that is resistant to a particular drug is enough to thwart a response to that drug. As a result, the clone with the worst response in a tumor will best explain a person’s overall treatment response.” 

More of Bertagnoli’s thoughts on this collaboration between scientists at Sanford Burnham Prebys and the NCI are available on the NIH director’s blog

Sanju Sinha, PhD, assistant professor in the Cancer Molecular Therapeutics Program at Sanford Burnham Prebys, is the first author on the featured study. 

Institute News

Media coverage of AI study predicting responses to cancer therapy ranks top 5% among published research

AuthorScott LaFee, Susan Gammon and Greg Calhoun
Date

April 29, 2024

Last week, Sanford Burnham Prebys and the National Cancer Institute shared findings regarding a first-of-its-kind computational tool to systematically predict patient response to cancer drugs at single-cell resolution.

Many news outlets and trade publications took note of this study and the computational tool’s potential future use in hospitals and clinics. This coverage placed the paper in the top 5% of all manuscripts ranked by Altmetric—a service that tracks and analyzes online attention of published research to improve the understanding and value of research and how it affects people and communities.

The results from the highlighted study were published on April 18, 2024, in the journal Nature Cancer.

“Our goal is to create a clinical tool that can predict the treatment response of individual cancer patients in a systematic, data-driven manner. We hope these findings spur more data and more such studies, sooner rather than later,” says first author Sanju Sinha, PhD, assistant professor in the Cancer Molecular Therapeutics Program at Sanford Burnham Prebys.

Here are a few of the venues that helped spread the word about this research: 

  • AP News: “Researchers … suggest that such single-cell RNA sequencing data could one day be used to help doctors more precisely match cancer patients with drugs that will be effective for their cancer.”
  • Politico, fourth story in Future Pulse newsletter: “Our hope is that being able to characterize the tumors on a single-cell resolution will enable us to treat and target potentially the most resistant and aggressive [cells], which are currently missed.”
  • NIH.gov: “The researchers discovered that if just one clone were resistant to a particular drug, the patient would not respond to that drug, even if all the other clones responded.”
  • Inside Precision Medicine: “The model was validated by predicting the response to monotherapy and combination treatment in three independent, recently published clinical trials for multiple myeloma, breast, and lung cancer.”

“I’m very pleased with how many news outlets covered our work,” Sinha says. “It is important and will help us continue improving the tool with more data so it can one day benefit cancer patients.”

Institute News

Ronai discusses new AI-supported breast cancer findings on Arabic-language TV

AuthorScott LaFee
Date

August 7, 2023

This month, researchers in Sweden published a study in The Lancet Oncology that compared the efficacy of artificial intelligence-supported mammogram screening versus the standard double reading by radiologists.

The researchers found in their randomized trial that AI-supported mammography screenings are safe, almost halved radiologists’ workload, and detected cancers that reviewing doctors missed.

Not surprisingly, the findings garnered international news coverage. Breast cancer is a global health threat, with more than 2.3 million women worldwide diagnosed each year and nearly 700,000 deaths.

Ze’ev Ronai, PhD, director of the Cancer Center at Sanford Burnham Prebys, was among experts interviewed by global media to provide context to the Swedish findings. He was interviewed on Alhurra, a U.S. government-owned Arabic-language satellite TV news channel that broadcasts internationally outside of the U.S.

You can watch the interview here. It’s in Arabic, but essentially Ronai said:

“This randomized trial of over 80,000 women offers an important advance for early detection of breast cancer, based on AI support of radiologist workload. AI will assist but not replace the role of radiologists in these assessments, and thus, is expected to enable radiologists to attend to more difficult cases. Caution from detections of less harmful lesions (which was one of the outcomes in this study), requires more training and careful validation. Overall, this is an important and safe advance in our quest for early detection of cancer, in this case, breast cancer.”

Institute News

Three big questions for cutting-edge biologist Will Wang

AuthorMiles Martin
Date

January 26, 2023

Will Wang’s spatial omics approach to studying neuromuscular diseases is unique.

He works at the intersection of biology and computer science to study how complex systems of cells interact, specifically focusing on the connections between nerves, muscles, and the immune response and their role in neuromuscular diseases.

We sat down with Wang, who recently joined the Institute as an assistant professor, to discuss his work and how computer technology is shaping the landscape of biomedical research.

How is your team taking advantage of computer technology to study neuromuscular diseases?

No cell exists in isolation. All our cells are organized into complex tissues with different types of cells interacting with each other. We study what happens at these points of interaction, such as where nerves connect to muscle cells. Combining many different types of data such as single cell sequencing, spatial proteomics, and measures of cell-cell signaling helps us get a more holistic look at how interactions between cells determine tissue function, as well as how these interactions are disrupted in injury and disease. Artificial neural networks help us make sense of these different types of data by finding patterns and insights the human brain can’t see on its own. And because computers can learn from the vast modality of data that we gather, we can also use them to help predict how biological systems will behave in the lab. The process goes both ways – from biology to computers and from computers to biology. 

How will these technologies shape the future of biomedical research?

Biology and computer programming are two different languages. There are a lot of mathematicians and programmers who are great at coming up with solutions to process data, but biological questions can get lost in translation and it’s easy to miss the bigger picture. And pure biologists don’t necessarily understand the full scope of what computers can do for them. If we’re going to get the most out of this technology in biomedical research, we need people with enough expertise in both areas that they can bridge the gap, which is what our lab is trying to do. Over time we’re going to see more and more labs that combine traditional biological experiments and data analysis approaches with artificial intelligence and machine learning. 

Are there any potential risks to these new technologies?

Artifical intelligence is here to accelerate discovery. Mundane tasks and measurements that took me weeks to carry out as a graduate student can be automated to a matter of minutes. We can now find patterns in high dimensional images that the human brain can’t easily visualize. However, any kind of artificial intelligence comes with a certain amount of risk if people don’t understand when and how to use the tools. If you just take the absolute word of the algorithm, there will inevitably be times where it’s not correct. As scientists, we use artificial intelligence as a cutting-edge discovery tool, but need to validate the findings in terms of the biology. At the end of the day, it is us, scientists, who are here to drive the discovery process and design real life experiments to make sure our therapies are safe and efficacious.